Literature DB >> 3943419

Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.

M Campieri, G A Lanfranchi, C Brignola, G Bazzocchi, P Gionchetti, M R Minguzzi, I P Cappello, C Corbelli, S Boschi.   

Abstract

In an attempt to know the exact retrograde spread of high-dosage 5-aminosalicylic acid enemas, we have studied eight patients with active left-sided colitis, by adding a small amount of barium sulfate to the enemas and by checking the spread radiologically after 15 minutes, 1 hour, and 6 hours. Four grams of 5-aminosalicylic acid in 100-ml enemas and 4 gm in 200-ml enemas were used. The same experiment was repeated in a subsequent attack, with enemas labeled with technetium-99m and checked by scintiscans in five of these patients. We always have observed a volume-dependent spread of enemas but, interestingly, in the patients studied with technetium-99m there was always a wider spread than that which was detected with barium enemas. In all five patients, 100-ml enemas reached the splenic flexure. In two patients with total colitis, a progression of 100-ml technetium-99m enemas was performed in the transverse colon, but the maximum opacity remained in the left side. We can conclude that 4 gm of 5-aminosalicylic acid in 100-ml enemas can be suitable for treating patients with left-sided colitis, and will represent a valid addition for patients with more extensive colitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943419     DOI: 10.1007/bf02555391

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

Review 1.  New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.

Authors:  M Campieri
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

3.  Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial.

Authors:  M Campieri; P Gionchetti; A Belluzzi; C Brignola; M Tampieri; P Iannone; G Brunetti; M Miglioli; L Barbara
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

Review 4.  Medical treatment of inflammatory bowel disease: new therapies, new drugs.

Authors:  L R Sutherland
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

5.  Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.

Authors:  M Campieri; P Gionchetti; A Belluzzi; C Brignola; M Migaldi; G M Tabanelli; G Bazzocchi; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

6.  Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.

Authors:  R A Vitti; F Meyers; L C Knight; J A Siegel; L S Malmud; R S Fisher
Journal:  Dig Dis Sci       Date:  1989-11       Impact factor: 3.199

7.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

8.  Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.

Authors:  M Campieri; P Paoluzi; G D'Albasio; G Brunetti; A Pera; L Barbara
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

9.  Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.

Authors:  M Campieri; C Corbelli; P Gionchetti; C Brignola; A Belluzzi; G Di Febo; P Zagni; G Brunetti; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

Review 10.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.